1)Hentges DJ:The anaerobic microflora of the human body. Clin Infect Dis 16:S175-S180, 1993
2)Brook I:Spectrum and treatment of anaerobic infectios. J Infect Chemother 22:1-13, 2016
3)日本化学療法学会,日本嫌気性菌感染症研究会:嫌気性菌感染症診断・治療ガイドライン2007,協和企画,2007
spp.;Report of 15 cases. Clin Microbiol Infect 20:O857-O860, 2014
菌血症7例の臨床的特徴.日臨微生物誌28:269-275, 2018
6)Panwalker AP:Unusual infections associated with colorectal cancer. Rev Infect Dis 10:347-364, 1988
rapidly identified by MALDI-TOF MS. A rare gram-variable agent of bacteraemia. Access Microbiol 2:acmi000137, 2020
;Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol 55:2234-2248, 2017
;Case report with literature review. Germs 10:51-54, 2020
, successfully treated with cefazolin and amoxicillin;A case report. Int Med Case Rep J 14:475-481, 2021
. Rev Infect Dis 1:278-290, 1979
属菌血症;亀田総合病院における7年間138症例の臨床的特徴.日臨微生物誌27:168-176, 2017
13)Brook I:Treatment of anaerobic infection. Expert Rev Anti infect Ther 5:991-1006, 2007
group and relatedspecies with special attenti on to carbapenems 2006-2009. Anaerobe 17:147-151, 2011
15)Zahar JR, et al:Incidence and clinical significance of anaerobic bacteraemia in cancer patients;A 6-year retrospective study. Clin Microbiol Infect 11:724-729, 2005
16)Nguyen MH, et al:Antimicrobial resistance and clinical outcome of bacteroides bacteremia;Findings of a multicenter prospective observational trial. Clin Infect Dis 30:870-876, 2000
17)Salonen JH, et al:Clinical significance and outcome of anaerobic bacteremia. Clin Infect Dis 26:1413-1417, 1998